Intravitreal Bevacizumab for diabetic retinopathy

Current Diabetes Reviews

Volumn 5, Issue 1, 2009, Pages 39-46

  Arevalo, J Fernando ^a   Garcia Amaris, Rafael A ^a  

^a Clinica Oftalmologica Centro Caracas   (Venezuela)

Author keywords

Diabetic macular edema; Intravitreal bevacizumab; Panretinal photocoagulation; Proliferative diabetic retinopathy; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANEURYSM; BLOOD VESSEL PERMEABILITY; CENTRAL SCOTOMA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG FATALITY; ENDOPHTHALMITIS; FOOT AMPUTATION; HEART INFARCTION; HUMAN; HYPERTENSION; IRIDOCYCLITIS; ISCHEMIA; LASER COAGULATION; NEOVASCULARIZATION (PATHOLOGY); OPTIC NERVE; PRIORITY JOURNAL; RETINA BLOOD VESSEL; RETINA DETACHMENT; RETINA TEAR; REVIEW; SIDE EFFECT; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS BODY; VITREOUS HEMORRHAGE; DRUG EFFECT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RECURRENT DISEASE; RETINA MACULA EDEMA; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; HUMANS; MACULAR EDEMA; NEOVASCULARIZATION, PATHOLOGIC; OPTIC NERVE; RECURRENCE; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 65549136079     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339909787314121     Document Type: Review

References (57)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7.
2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: diabetic macular edema. Ophthalmology 1984; 91: 1464-74.
3. Wormald R, Smeeth L, Henshaw K. Medical interventions for diabetic retinopathy. In: Wormald R, Smeeth L, Henshaw K, Eds. Evidence-Based Ophthalmology. London: BMJ Books; 2004; 331.
4. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-50.
5. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
6. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995; 72: 638-45.
7. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-11.
8. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994; 112: 1476-82.
9. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002; 133: 373-85.
10. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103: 1820-8.
11. Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angio-poietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005; 139: 476-81.
12. Cunningham ET Jr, Adamis AP, Altaweel M, et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-57.
13. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al.; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007; 114: 743-50.
14. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113: 23-8.
15. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 275-8.
16. Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye2007 Sep 21.
17. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
18. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-47.
19. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72.
20. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26: 279-84.
21. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695.e1-15.
22. Mason JO 3rd, Nixon PA, White MF. Intravitreal injection of bevacizumab (avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142: 685-8.
23. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 270-4.
24. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26: 262-9.
25. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26: 257-61.
26. Pieramici DJ, Avery RL, Castellarin AA, Nasir MA, Rabena M. Case of anterior uveitis after intravitreal injection of bevacizumab. Retina 2006; 26: 841-2.
27. Meyer CH, Mennel S, Schmidt JC, Kroll P. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol 2006; 90: 1207-8.
28. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2007 Aug 3.
29. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796-06.
30. Ferris FL 3rd, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984; 28(Suppl): 452-61.
31. Bresnick GH. Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology 1983; 90: 1301-17.
32. Strom C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci 2005; 46: 3855-8.
33. Campochiaro PA; C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 2004; 45: 922-31.
34. Nguyen QD, Shah SM, Van Anden E, Sung JU, Vitale S, Campochiaro PA. Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci 2004; 45: 617-24.
35. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injection of ranimizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006; 113: 1706-12.
36. Aylward GW, Pearson RV, Jagger JD, Hamilton AM. Extensive argon laser photocoagulation in the treatment of proliferative diabetic retinopathy. Br J Ophthalmol 1989; 73: 197-201.
37. Doft BH, Blankenship GW. Single versus multiple treatment sessions of argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1982; 89: 772-9.
38. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS): DRS report 8. Ophthalmology 1981; 88: 583-600.
39. Randomized comparison of krypton versus argon scatter photocoagulation for diabetic disc neovascularization: the Krypton Argon Regression Neovascularization Study report number 1. Ophthalmology 1993; 100: 1655-64.
40. Nonaka A, Kiryu J, Tsujikawa A, et al. Inflammatory response after scatter laser photocoagulation in nonphotocoagulated retina. Invest Ophthalmol Vis Sci 2002; 43: 1204-9.
41. Tsujikawa A, Kiryu J, Dong J, et al. Quantitative analysis of diabetic macular edema after scatter laser photocoagulation with the scanning retinal thickness analyzer. Retina 1999; 19: 59-64.
42. Kaufman SC, Ferris FL III, Seigel DG, Davis MD, DeMets DL. Factors associated with visual outcome after photocoagulation for diabetic retinopathy: Diabetic Retinopathy Study Report 13. Invest Ophthalmol Vis Sci 1989; 30: 23-8.
43. Fong DS, Ferris FL III, Davis MD, Chew EY. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report No. 24. Am J Ophthalmol 1999; 127: 137-41.
44. Ferris FL III, Podgor MJ, Davis MD. Macular edema in Diabetic Retinopathy Study (DRS): DRS report number 12. Ophthalmology 1987; 94: 754-60.
45. McDonald HR, Schatz H. Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1985; 92: 388-93.
46. Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M. Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003; 110: 2386-94.
47. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
48. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
49. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular specific growth factor and blood vessel formation. Nature 2000; 407: 242-8.
50. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-80.
51. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 352-4.
52. Isaacs TW, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 2006; 34: 802-3.
53. Friedlander SM, Welch RM. Vanishing disc neovascularization following intravitreal bevacizumab (Avastin) injection. Arch Ophthalmol 2006; 124: 1365.
54. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006; 26: 699-700.
55. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-86.
56. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13.
57. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long term visual results. Ophthalmology 1991; 98: 1594-1602.